HTG Molecular Diagnostics (NASDAQ:HTGM)‘s stock had its “buy” rating restated by stock analysts at Cantor Fitzgerald in a report released on Friday. They currently have a $7.00 price target on the medical research company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 91.78% from the stock’s current price.

The analysts wrote, “. We reiterate our Overweight rating and 12-month price target of $7 on shares of HTGM. HTG reported 3Q18 revenue of $4.7MM (+26%), $0.4MM below FactSet consensus. Product and service RUO revenue was lighter than our expectations, but was offset by strong revenue from Collaboration Agreements. HTG expects to achieve the midpoint of its previously indicated 2018 revenue guidance ($21-25MM), implying 17% top-line growth in 4Q. We think momentum is starting to pick up for HTG with a number of drivers in the business expected to materialize in late 2018 into 2019.””

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of HTG Molecular Diagnostics in a report on Thursday, August 16th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Tuesday, August 14th. Finally, ValuEngine lowered shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Thursday, July 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $6.25.

NASDAQ HTGM traded down $0.49 on Friday, hitting $3.65. The stock had a trading volume of 610,059 shares, compared to its average volume of 382,269. The company has a current ratio of 9.50, a quick ratio of 9.29 and a debt-to-equity ratio of 0.35. HTG Molecular Diagnostics has a 52-week low of $1.71 and a 52-week high of $5.83. The firm has a market capitalization of $118.23 million, a P/E ratio of -2.04 and a beta of 2.03.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. HTG Molecular Diagnostics had a negative net margin of 81.10% and a negative return on equity of 132.67%. The business had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.14 million. As a group, sell-side analysts predict that HTG Molecular Diagnostics will post -0.7 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of HTG Molecular Diagnostics by 2.9% during the third quarter. FMR LLC now owns 3,588,045 shares of the medical research company’s stock worth $18,120,000 after buying an additional 100,000 shares during the period. Stonepine Capital Management LLC acquired a new stake in shares of HTG Molecular Diagnostics during the second quarter worth $5,506,000. Putnam Investments LLC lifted its stake in shares of HTG Molecular Diagnostics by 31.4% during the second quarter. Putnam Investments LLC now owns 1,387,883 shares of the medical research company’s stock worth $4,524,000 after buying an additional 331,690 shares during the period. Private Wealth Partners LLC lifted its stake in shares of HTG Molecular Diagnostics by 11.1% during the third quarter. Private Wealth Partners LLC now owns 1,000,000 shares of the medical research company’s stock worth $5,050,000 after buying an additional 100,000 shares during the period. Finally, Granahan Investment Management Inc. MA lifted its stake in shares of HTG Molecular Diagnostics by 14.1% during the second quarter. Granahan Investment Management Inc. MA now owns 915,449 shares of the medical research company’s stock worth $2,984,000 after buying an additional 112,928 shares during the period. Institutional investors and hedge funds own 50.55% of the company’s stock.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

Featured Article: Earnings Per Share (EPS)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.